| Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. | retinoblastoma, |
| Expression of p28GANK and its correlation with RB in human hepatocellular carcinoma. | liver, |
| Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. | liver, |
| Gankyrin oncoprotein overexpression as a critical factor for tumor growth in human esophageal squamous cell carcinoma and its clinical significance. | esophageal, |
| Expression of the oncoprotein gankyrin and phosphorylated retinoblastoma protein in human testis and testicular germ cell tumor. | testicular,retinoblastoma, |
| This study identifies gankyrin, for the first time, as new potential predictive and oncogenic factor of well-differentiated/dedifferentiated liposarcoma, suggesting the potential for service as a future Liposarcoma therapeutic approach. | sarcoma, |
| MAGE-A4 binds to gankyrin and suppresses its oncogenic activity. | None |
| Crystal structure of the homolog of the oncoprotein gankyrin, an interactor of Rb and CDK4/6. | None |
| The oncoprotein gankyrin negatively regulates both p53 and RB by enhancing proteasomal degradation. | None |
| Structure of the oncoprotein gankyrin in complex with S6 ATPase of the 26S proteasome. | None |
| gankyrin plays an oncogenic role mainly at the early stages of human hepatocarcinogenesis. | None |
| Roles of heat shock factor 1 and 2 in response to proteasome inhibition: consequence on p53 stability. | None |
| The oncoprotein p28GANK establishes a positive feedback loop in beta-catenin signaling. | None |
| Resurfaced shape complementary proteins that selectively bind the oncoprotein gankyrin. | None |
| Characterization of the binding interaction between the oncoprotein gankyrin and a grafted S6 ATPase. | None |
| Gankyrin is an oncoprotein that facilitates the degradation of two key tumor suppressors, namely, Rb and p53. Gankyrin is involved in the regulation of cell signaling pathways, with particular reference to RhoA/ROCK/PTEN/PI3K/Akt, beta-catenin, IL-6/STAT3, and IL-1beta/IRAK-1 inflammatory signaling. Review. | None |
| [Synthesis and immunogenic properties of peptides corresponding to the 200-210 site of the oncoprotein p28sis]. | None |